Leqembi’s sales curve just got a new number. BioArctic investors may not ignore it
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.